The Quantitative Indices of ERCC1 Expression in Serous Ovarian Cancer Tissue and the Efficacy of First-Line Platinum-Based Chemotherapy
Platinum-based drugs are widely used in clinical practice. Their efficacy varies widely among patients, which may be due to a disruption of the expression of ERCC1 - excision repair protein. In the prospective study a strictly quantitative analysis of the ERCC1 protein expression was carried out in...
Saved in:
| Main Authors: | T. A. Bogush, M. B. Stenina, E. A. Bogush, V. T. Zarkua, S. A. Kalyuzhny, I. A. Mamichev, A. S. Tyulyandina, S. A. Tyulyandin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC "Publishing House OKI"
2020-05-01
|
| Series: | Антибиотики и Химиотерапия |
| Subjects: | |
| Online Access: | https://www.antibiotics-chemotherapy.ru/jour/article/view/65 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs
by: T. A. Bogush, et al.
Published: (2020-05-01) -
A Systematic Review of SNPs Screening for Platinum-Related Pharmacodynamics and Pharmacokinetics Genes in Non-Small Cell Lung Cancer for Precision Medicine
by: Afifah NN, et al.
Published: (2025-06-01) -
Trichothiodystrophy due to ERCC2 Variants: Uncommon Contributor to Progressive Hypomyelinating Leukodystrophy
by: Ali Reza Tavasoli, et al.
Published: (2025-02-01) -
ERCC1/NGFR affects prognosis in basal-like breast cancer
by: Yuxi Lei, et al.
Published: (2025-07-01) -
A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma
by: Ruiling Xu, et al.
Published: (2025-07-01)